Refine
Has Fulltext
- yes (54)
Is part of the Bibliography
- yes (54) (remove)
Year of publication
Document Type
- Journal article (54)
Language
- English (54)
Keywords
- chronic kidney disease (12)
- Fabry disease (11)
- enzyme replacement therapy (5)
- hemodialysis (5)
- mortality (4)
- type 2 diabetes (4)
- cardiovascular events (3)
- end-stage renal disease (3)
- epidemiology (3)
- Chronic kidney disease (2)
- Diabetes mellitus (2)
- Enzyme replacement therapy (2)
- Fabry nephropathy (2)
- Kidney function (2)
- United States (2)
- blood pressure (2)
- cardiomyopathy (2)
- cardiovascular disease (2)
- cardiovascular morbidity (2)
- convection volume (2)
- diabetes (2)
- diabetes mellitus (2)
- dialysis (2)
- dialysis adequacy (2)
- fibrosis (2)
- genome-wide association (2)
- glomerular filtration rate (2)
- glycemic control (2)
- heart failure (2)
- hemodiafiltration (2)
- hypertrophic cardiomyopathy (2)
- kidney (2)
- left ventricular hypertrophy (2)
- proteinuria (2)
- safety (2)
- stage renal-disease (2)
- 2-dimensional speckle tracking (1)
- A-delta fibers (1)
- ACC/AHA classification (1)
- ASE formula (1)
- African-americans (1)
- Agalsidase beta (1)
- Alpha-Galactosidase (1)
- Alpha-galactosidase (1)
- Amino acids (1)
- Anderson-Fabry Disease (1)
- CKD (1)
- CMR (1)
- Calcium Citrate (1)
- Cardiomyopathy (1)
- Cardiovascular diseases (1)
- Catheter Lock Solution (1)
- Catheter-related Bloodstream Infections (CRBSI) (1)
- Chronic Kidney-disease (1)
- Chronic kidney-disease (1)
- Clinical proteomics (1)
- Clinical trial (1)
- Clinical-trials (1)
- Cohort study (1)
- Cumulative incidence function (1)
- D313Y genotype (1)
- Diabetic nephropathies (1)
- Diabetic-nephropathy (1)
- Dipeptidyl-peptidase IV inhibitors (1)
- Discovery (1)
- Diversity (1)
- EUROASPIRE survey (1)
- Epidemiology (1)
- European Society (1)
- Fabry (1)
- Fabry cardiomyopathy (1)
- Fabry genotype (1)
- Fabry patient (1)
- Fabry phenotype (1)
- Fabry-associated pain (1)
- Family Investigation of Nephropathy and Diabetes (1)
- Female patients (1)
- Galactosidase-A gene (1)
- General-population (1)
- Globotriaosylceramide (1)
- Glomerular-filtration-rate (1)
- Glycaemic control (1)
- HLA (1)
- Haemodialysis (1)
- Hazards (1)
- Heart failure (1)
- Hemodialysis-patients (1)
- Hemoglobin A1C (1)
- Homoarginine (1)
- ICD-coding of CKD (1)
- Insulin therapy (1)
- KDIGO (1)
- L-arginine (1)
- LDL cholesterol (1)
- LV mass (1)
- Lag time (1)
- Linagliptin (1)
- Lyso-Gb3 (1)
- Mass-spectrometry (1)
- Model (1)
- Mortality (1)
- Natural-history data (1)
- Network (1)
- New mexico (1)
- Nrf2 (1)
- Onset hypertrophic cardiomyopathy (1)
- Oral antidiabetic drugs (1)
- Outcome survey (1)
- Pain (1)
- Pain-related evoked potentials (1)
- Postmarketing Experience (1)
- Prevalence (1)
- Probabilities (1)
- Progression (1)
- Quality of life (1)
- Racial differences (1)
- Regression (1)
- Research design (1)
- Risk (1)
- SF-36 (1)
- SGLT2 inhibitor (1)
- Sample-sizes (1)
- Small fiber neuropathy (1)
- Stage renal-disease (1)
- Subdistribution (1)
- Sudden cardiac death (1)
- Taurolidine (1)
- Teichholz formula (1)
- Tests (1)
- Treatment outcome (1)
- VEMP (1)
- Variants (1)
- X-chromosomal inactivation (1)
- Young-patients (1)
- activated-receptor gamma (1)
- add-on (1)
- agalsidase-beta (1)
- agnoists (1)
- albumin excretion rate (1)
- albuminuria (1)
- aldosterone (1)
- alkaline phosphatase (1)
- alpha galactosidase (1)
- alpha-galactosidase-A (1)
- alpha/delta agonist GFT505 (1)
- anaemia (1)
- anemia (1)
- antagonist (1)
- anti-drug antibodies (1)
- anticoagulation (1)
- antidiabetic agents (1)
- arial fibrillation (1)
- atherogenic dyslipidaemia (1)
- atherosclerosis risk (1)
- bardoxolone methyl (1)
- biocompatibility (1)
- biomarker (1)
- biopsy (1)
- biopsy findings (1)
- blood-glucose control (1)
- body weight (1)
- calcification (1)
- canagliflozin (1)
- cancer risk factors (1)
- cardiac dysfunction (1)
- cardiac energy metabolism (1)
- cardiac hypertrophy (1)
- cardiovascular death (1)
- cardiovascular magnetic resonance (1)
- cardiovascular magnetic-resonance (1)
- cardiovascular mortality (1)
- cardiovascular munster procam (1)
- cardiovascular outcomes (1)
- cardiovascularm disease (1)
- chronic kidney-disease (1)
- clinical manifestations (1)
- clinical trial (1)
- colestilan (1)
- comorbidity (1)
- consensus conference (1)
- converting enzyme-inhibition (1)
- cornea verticillata (1)
- coronary artery disease (1)
- coronary heart disease (1)
- cortisol (1)
- costs (1)
- creatine synthesis (1)
- cryptogenic stroke (1)
- diabetes complications (1)
- diabetes mellitus type 2 (1)
- diabetic kidney disease (1)
- diabetic mouse (1)
- diabetic nephropathy (1)
- diagnosis (1)
- diagnosis in Fabry disease (1)
- dietary sodium restriction (1)
- disease (1)
- doule blind (1)
- dysfunction (1)
- echocardiography (1)
- efficacy (1)
- empagliflozin (1)
- end stage renal disease (1)
- end-stage kidney disease (1)
- erythropoietin (1)
- fabry disease (1)
- failure (1)
- female Fabry patients (1)
- ferritin (1)
- fibroblast growth factor-23 (1)
- focal semental glomerulosclerosis (1)
- fractionation membranev (1)
- free light chains (1)
- gene variant (1)
- genetic renal disease (1)
- genetics (1)
- genome-wide association study (1)
- genotype/phenotype correlation (1)
- genotyping (1)
- global outcomes (1)
- glomerular-filtration-rate (1)
- glomerulonephritis (1)
- haemodiafiltration (1)
- hearing loss (1)
- hemoglobin (1)
- heodialysis patients (1)
- high denisty lipoprotein (1)
- hypercholesterolemia (1)
- hyperphosphataemia (1)
- hypersensitivity (1)
- identification (1)
- immunofluorescence (1)
- impact (1)
- incidence (1)
- induced insulin-release (1)
- infections (1)
- inflammation (1)
- inherited metabolic disorders (1)
- inos (1)
- insufficiency (1)
- intensive glucose control (1)
- iron (1)
- ischemia-reperfusion injury (1)
- italian population (1)
- kidney disease (1)
- left ventricular mass (1)
- left ventricular mass index (1)
- left-ventricular hypertrophy (1)
- linkage (1)
- lipoprotein apheresis (1)
- lipoprotein(a) (1)
- lysosomal storage disease (1)
- lysosomal storage disorder (1)
- macrovascular (1)
- medical dialysis (1)
- medium cut-off dialyzer (1)
- melanoma (1)
- men born (1)
- metformin (1)
- mices (1)
- microvascular (1)
- mineral metabolism (1)
- multiple sclerosis (1)
- myocardial infarction (1)
- myocardial fibrosis (1)
- natural history (1)
- natural-history data (1)
- nerve fibers (1)
- neuropathy (1)
- nictric-oxide (1)
- overload (1)
- oxidative stress (1)
- parathyroid hormone (1)
- pathophysiology (1)
- patients’ awareness (1)
- phase IV (1)
- phosphate homeostasis (1)
- phospholipid fatty acids (1)
- physicians’ awareness (1)
- pioglitazone (1)
- placebo (1)
- placebo-controlled trial (1)
- podocyte (1)
- prediction model (1)
- prevalence (1)
- protein-bound uremic toxins (1)
- randomized controlled trial (1)
- randomized controlled-trial (1)
- randomized trial (1)
- rat kidney (1)
- receptor (1)
- recombination hotspot (1)
- renal disease (1)
- renal dysfunction (1)
- renal fibrosis (1)
- renal function (1)
- renal replacement therapy (1)
- renal system (1)
- renoprotection (1)
- replacement therapy (1)
- residual cardiovascular risk (1)
- risk (1)
- risk factors (1)
- septal hypertrophy (1)
- serum creatinine (1)
- sevelamer (1)
- single nucleotide polymorphisms (1)
- skin diseases (1)
- sudden cardiac death (1)
- sulfonylurea (1)
- survival (1)
- term fenofibrate therapy (1)
- therapeutic options (1)
- therapy (1)
- trial design (1)
- triglyceride-rich lipoproteins (1)
- troponin T (1)
- type 2 (1)
- type-1 diabetes mellitus (1)
- type-2 diabetes mellitus (1)
- urinary protein excretion (1)
- vertigo (1)
- vitamin D (1)
Institute
- Medizinische Klinik und Poliklinik I (54) (remove)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 602133 (1)
Background
The importance of chronic kidney disease (CKD) and anaemia has not been comprehensively studied in asymptomatic patients at risk for heart failure (HF) versus those with symptomatic HF. We analysed the prevalence, characteristics and prognostic impact of both conditions across American College of Cardiology/American Heart Association (ACC/AHA) precursor and HF stages A–D.
Methods and results
2496 participants from three non-pharmacological German Competence Network HF studies were categorized by ACC/AHA stage; stage C patients were subdivided into C1 and C2 (corresponding to NYHA classes I/II and III, respectively). Overall, patient distribution was 8.1%/35.3%/32.9% and 23.7% in ACC/AHA stages A/B/C1 and C2/D, respectively. These subgroups were stratified by the absence ( – ) or presence ( +) of CKD (estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73m2) and anaemia (haemoglobin in women/men < 12/ < 13 g/dL). The primary outcome was all-cause mortality at 5-year follow-up. Prevalence increased across stages A/B/C1 and C2/D (CKD: 22.3%/23.6%/31.6%/54.7%; anaemia: 3.0%/7.9%/21.7%/33.2%, respectively), with concordant decreases in median eGFR and haemoglobin (all p < 0.001). Across all stages, hazard ratios [95% confidence intervals] for all-cause mortality were 2.1 [1.8–2.6] for CKD + , 1.7 [1.4–2.0] for anaemia, and 3.6 [2.9–4.6] for CKD + /anaemia + (all p < 0.001). Population attributable fractions (PAFs) for 5-year mortality related to CKD and/or anaemia were similar across stages A/B, C1 and C2/D (up to 33.4%, 30.8% and 34.7%, respectively).
Conclusions
Prevalence and severity of CKD and anaemia increased across ACC/AHA stages. Both conditions were individually and additively associated with increased 5-year mortality risk, with similar PAFs in asymptomatic patients and those with symptomatic HF.